BidaskClub upgraded shares of Illumina (NASDAQ:ILMN) from a buy rating to a strong-buy rating in a report issued on Thursday.
Several other research analysts have also issued reports on ILMN. Zacks Investment Research lowered Illumina from a buy rating to a hold rating in a research report on Tuesday, December 26th. Wells Fargo raised Illumina from a market perform rating to an outperform rating and set a $205.00 price target on the stock in a research note on Tuesday, January 2nd. Evercore ISI started coverage on Illumina in a research note on Wednesday, January 3rd. They issued an outperform rating and a $250.00 price target on the stock. Piper Jaffray lifted their price target on Illumina to $274.00 and gave the company an overweight rating in a research note on Thursday, January 4th. Finally, BTIG Research started coverage on Illumina in a research note on Friday, January 5th. They issued a neutral rating on the stock. One research analyst has rated the stock with a sell rating, six have assigned a hold rating, sixteen have assigned a buy rating and one has given a strong buy rating to the company. The stock has a consensus rating of Buy and a consensus price target of $243.03.
Shares of NASDAQ:ILMN traded down $1.34 during midday trading on Thursday, hitting $244.50. The company had a trading volume of 248,538 shares, compared to its average volume of 866,458. Illumina has a 12 month low of $167.98 and a 12 month high of $256.64. The company has a quick ratio of 3.55, a current ratio of 3.99 and a debt-to-equity ratio of 0.43. The firm has a market capitalization of $36,686.40, a P/E ratio of 61.24, a P/E/G ratio of 3.33 and a beta of 0.89.
Illumina (NASDAQ:ILMN) last posted its quarterly earnings results on Tuesday, January 30th. The life sciences company reported $1.44 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of $1.22 by $0.22. Illumina had a return on equity of 21.71% and a net margin of 26.56%. The business had revenue of $778.00 million for the quarter, compared to analyst estimates of $752.04 million. During the same period last year, the company earned $0.85 EPS. The firm’s revenue was up 25.7% on a year-over-year basis. equities research analysts expect that Illumina will post 4.6 earnings per share for the current year.
In related news, Director Robert S. Epstein sold 1,250 shares of Illumina stock in a transaction dated Monday, January 29th. The stock was sold at an average price of $244.18, for a total transaction of $305,225.00. Following the completion of the transaction, the director now owns 8,588 shares in the company, valued at $2,097,017.84. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Also, SVP Oene Mark Van sold 1,400 shares of Illumina stock in a transaction dated Thursday, April 12th. The stock was sold at an average price of $238.48, for a total value of $333,872.00. Following the transaction, the senior vice president now owns 12,217 shares of the company’s stock, valued at approximately $2,913,510.16. The disclosure for this sale can be found here. In the last ninety days, insiders sold 18,008 shares of company stock worth $4,130,075. 0.54% of the stock is owned by company insiders.
A number of institutional investors have recently bought and sold shares of ILMN. Financial Gravity Companies Inc. bought a new position in Illumina during the fourth quarter worth about $106,000. SeaCrest Wealth Management LLC bought a new position in Illumina during the fourth quarter worth about $154,000. Captrust Financial Advisors bought a new position in Illumina during the fourth quarter worth about $165,000. Mitsubishi UFJ Securities Holdings Co. Ltd. grew its holdings in Illumina by 113.9% during the fourth quarter. Mitsubishi UFJ Securities Holdings Co. Ltd. now owns 770 shares of the life sciences company’s stock worth $168,000 after purchasing an additional 410 shares during the period. Finally, Riverbridge Partners LLC bought a new position in Illumina during the fourth quarter worth about $202,000. Institutional investors and hedge funds own 91.68% of the company’s stock.
ILLEGAL ACTIVITY WARNING: This news story was first reported by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are reading this news story on another website, it was stolen and reposted in violation of international trademark & copyright laws. The original version of this news story can be read at https://www.dispatchtribunal.com/2018/04/20/illumina-ilmn-stock-rating-upgraded-by-bidaskclub.html.
Illumina Company Profile
Illumina, Inc provides sequencing and array-based solutions for genetic analysis. The company operates in two segments, Core Illumina and Consolidated VIEs. It offers sequencing by synthesis technology that provides researchers with various applications and the ability to sequence mammalian genomes; and arrays for a range of deoxyribonucleic acid and RNA analysis applications, including single nucleotide polymorphism genotyping, copy number variations analysis, gene expression analysis, and methylation analysis, as well as allow the detection of known genetic markers on a single array.
Receive News & Ratings for Illumina Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Illumina and related companies with MarketBeat.com's FREE daily email newsletter.